Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.40 |
| ▸ | CCR5 | P51681 | 4/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5252193 | 0.99 | PPARG (0.43) | PPARGLMNAMAPTNPSR1CCR2 | |
| SCHEMBL6415211 | 0.91 | ROCK2 (0.46) | LMNAMAPTNPSR1ROCK2ROCK1 | |
| SCHEMBL6409427 | 0.91 | ROCK2 (0.46) | PPARGLMNAMAPTCCR2ROCK2 | |
| SCHEMBL6410472 | 0.90 | MAPT (0.43) | LMNAMAPTNPSR1ROCK2ROCK1 | |
| SCHEMBL6409171 | 0.90 | ROCK2 (0.45) | PPARGCCR2ROCK2ROCK1CCR5 | |
| Hydrochloric Acid SCHEMBL6416127 | 0.90 | ROCK2 (0.45) | LMNAMAPTNPSR1ROCK2ROCK1 | |
| SCHEMBL6411114 | 0.90 | SIGMAR1 (0.42) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL6411840 | 0.90 | ROCK2 (0.45) | PPARGLMNAMAPTCCR2ROCK2 | |
| Hydrochloric Acid SCHEMBL6415308 | 0.90 | MAPT (0.43) | LMNAMAPTNPSR1ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL6414756 | 0.90 | ROCK2 (0.45) | PPARGCCR2ROCK2ROCK1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | PPARG 171/4885LMNA 3107/4885MAPT 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.